Zaofeng Yang

Zaofeng Yang

Auto-generated profile, based on publicly available information

Zaofeng Yang

Department of Microbiology and Immunology, Columbia University, New York, NY 10032, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2024 in Science Immunology
Verified
Journal Article
Closed access
FLFangda Li
Fangda Li
ZYZaofeng Yang
Zaofeng Yang
TSThomas M. Savage
Thomas M. Savage
RVRosa L. Vincent
Rosa L. Vincent
KSKenia de Los Santos-Alexis
Kenia de Los Santos-Alexis
NANicholas Arpaia
Nicholas Arpaia
Interferon-γ (IFN-γ) is a potent cytokine critical for response to immunotherapy, yet conventional methods to systemically deliver this cytokine have been hindered by severe dose-limiting toxicities. Here, we engineered a strain of probiotic bacteria that home to tumors and locally release IFN-γ. A single intratumoral injection of these IFN-γ–producing bacteria was sufficient to drive systemic tumor antigen–specific antitumor immunity, without observable toxicity. Although cancer cells use various resistance mechanisms to evade immune responses, bacteria-derived IFN-γ overcame primary resistance to programmed cell death 1 (PD-1) blockade via activation of cytotoxic Foxp3 − CD4 + and CD8 + T cells. Moreover, by activating natural killer (NK) cells, bacteria-derived IFN-γ also overcame acquired resistance mechanisms to PD-1 blockade, specifically loss-of-function mutations in IFN-γ signaling and antigen presentation pathways. Collectively, these results demonstrate the promise of combining IFN-γ–producing bacteria with PD-1 blockade as a therapeutic strategy for overcoming immunotherapy-resistant, locally advanced, and metastatic disease.

14 May 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
BHBradley S. Heater
Bradley S. Heater
ZYZaofeng Yang
Zaofeng Yang
MLMarianne M. Lee
Marianne M. Lee
MCMichael K. Chan
Michael K. Chan

1 October 2019 in Biomaterials
Verified
Journal Article
Closed access
ZYZaofeng Yang
Zaofeng Yang
JZJiale Zheng
Jiale Zheng
CCChin-Fung Chan
Chin-Fung Chan
IWIris L.K. Wong
Iris L.K. Wong
BHBradley S. Heater
Bradley S. Heater
MCMichael K. Chan
Michael K. Chan

14 September 2022 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
ZYZaofeng Yang
Zaofeng Yang
JSJacquelyne Ka-Li Sun
Jacquelyne Ka-Li Sun
MLMarianne Lee
Marianne Lee
MCMichael K. Chan
Michael K. Chan
Background: Although immune checkpoint inhibitors (ICIs) have been shown to yield promising therapeutic outcomes in a small subset of patients with triple negative breast cancer (TNBC), the majority of patients either do not respond or subsequently develop resistance. Recent studies have revealed the critical role of TP53 gene in cancer immunology. Loss or mutation of p53 in cancer cells has been found to promote their immune escape. Given the high mutation frequency of TP53 in TNBC cells, restoration of p53 function could be a potential strategy to overcome their resistance to anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) therapy. Herein, we have assessed the use of Pos3Aa crystal-based platform to mediate the intracellular delivery of p53 protein to restore p53 activity in p53 null tumors and consequently augment anti-PD-1 activity. Methods: The efficiency of Pos3Aa-p53 crystals in delivering p53 protein was evaluated using confocal imaging, immunofluorescence staining, flow cytometry and RNA-seq. The ability of Pos3Aa-p53 crystals to remodel tumor microenvironment was investigated by examining the markers of immunogenic cell death (ICD) and the expression of PD-L1, indoleamine 2,3-dioxygenase 1, tryptophan 2,3-dioxygenase 2 and type I interferon (IFN). Finally, both unilateral and bilateral 4T1 tumor mouse models were utilized to assess the efficacy of Pos3Aa-p53 crystal-mediated p53 restoration in enhancing the antitumor activity of ICIs. T cells in tumor tissues and spleens were analyzed, and the in vivo biosafety of the Pos3Aa-p53 crystal/anti-PD-1 antibody combination was also evaluated. Results: Delivery of p53 protein into p53-null TNBC 4T1 cells via Pos3Aa-p53 crystals restored the p53 activity, and therefore led to the induction of ICD, activation of type I IFN signaling and upregulation of PD-L1 expression. Pos3Aa-p53 crystals significantly enhanced T cell infiltration and activation in 4T1 tumors, thereby sensitizing them to anti-PD-1 therapy. The combination of Pos3Aa-p53 crystals with anti-PD-1 antibody also induced a systemic antitumor immunity resulting in the inhibition of distal tumor growth with minimal toxicity. Conclusion: This study validates that p53 restoration can be an effective approach to overcome ICI resistance and demonstrates that intracellular delivery of p53 protein can be an efficient, safe and potentially universal strategy to restore p53 activity in tumors carrying TP53 mutation.

1 June 2020 in iScience
Verified
Journal Article
Open access
ZYZaofeng Yang
Zaofeng Yang
BHBradley S. Heater
Bradley S. Heater
CCClayton T. Cuddington
Clayton T. Cuddington
APAndre F. Palmer
Andre F. Palmer
MLMarianne Lee
Marianne Lee
MCMichael K. Chan
Michael K. Chan
The effectiveness of cancer radiotherapy is frequently hindered by the hypoxia of the tumor microenvironment. Direct delivery of oxygen to hypoxic tumor tissues is an attractive strategy to overcome this hypoxia-associated radioresistance. Herein, we report the generation of submicron-sized particles comprising myoglobin fused to the crystal-forming domain of Cry3Aa protein for the targeted delivery of oxygen to cancer cells. We demonstrate that myoglobin-containing particles were successfully produced in Bacillus thuringiensis with the assistance of the Cry3Aa domain I. Furthermore, these particles could be genetically modified to incorporate the cell penetrating peptide TAT and cell targeting peptide A549.1, resulting in particles that exhibited improved cellular uptake and targeting toward A549 cells. Notably, these myoglobin-containing particles increased the intracellular oxygen levels of A549 cells and thereby sensitized them to radiation. These findings suggest that the targeted delivery of O2-bound myoglobin could be an effective approach to enhance the efficacy of radiotherapy.

18 June 2018 in Journal of Molecular Histology
Verified
Journal Article
Closed access
PDF file
XLXue Liu
Xue Liu
YLYingying Liu
Yingying Liu
ZYZaofeng Yang
Zaofeng Yang
WNWen Ning
Wen Ning